6 9 Discovery: We are broadening our portfolio of investigational medicines to tackle additional high prevalence causes of severe vision loss Glaucoma GA Ocular Inflammation ~80M 4 ~5M 2 ~800K 1 1. Nila Kirupaharan et al. Invest. Ophthalmol. Vis. Sci. 2024;65(7):6510. 2. Rudnicka AR, et al. Ophthalmology 2012;119:571–580. 3. Wong WL, et al. Lancet Glob Health 2014;2:e106–116. 4. Allison K et al. Cureus . 2020 Nov 24;12(11):e11686. 5. Ehrlich JR, et al. JAMA Ophthalmol. 2024;142(11):1046–1053. ~1M U.S. 3 ~4M U.S. 5 Pre-IND Bispecific Antibodies: KSI-102: anti-IL-6, anti-TNF α KSI-103: anti-IL-6, anti-IL-1 Ocular Inflammation Pre-clinical ABC ® Duet: Inhibitor of NLRP3 inflamma- some + IOP Lowering Glaucoma Pre-clinical Bispecific Antibodies: anti-IL-6 , anti-complement; anti-VEGF, anti-complement Geographic Atrophy ABC: antibody biopolymer conjugate GA: geographic atrophy Estimated global prevalence ABC ® Duet: Inhibitor of NLRP3 inflamma- some + Complement